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Alzheimer's disease is a complex, multifactorial, neurodegenerative
disease. It is the leading cause of dementia in elderly people. The main
pathologic features of Alzheimer's disease are neurofibrillary tangles
and senile plaque formation in the brain. The latter is caused by the pro-
gressive deposition of mainly 39- to 43-amino acid amyloid β (Aβ) pep-
tides generated by proteolytic cleavage of the amyloid precursor protein
(APP). The systematic observation of changes in APP metabolism in
monogenic forms of Alzheimer's disease suggested that the Aβ/APP path-
way is at the heart of the disease (Hardy and Selkoe, 2002). Even though
the key role of APP processing in the etiology of Alzheimer's disease has
been challenged in recent years, recent genetic and GWAS studies of spo-
radic formsof Alzheimer's disease seem to support the importance of dys-
functional APPmetabolismandAβpeptide production/degradation in the
physiopathology of Alzheimer's disease (Lambert and Amouyel, 2011;
Jonsson et al., 2012; Tian et al., 2013; Young et al., 2015).
The twomajor Aβ peptide species (Aβx-40 andAβx-42) are produced
by the sequential endoproteolysis of APP by β-secretase and γ-secretase
complexes. APP can also undergo non-amyloidogenic cleavage by α-
secretase within the Aβ sequence, which thereby precludes Aβ genera-
tion. The various enzymes and protein complexes involved in these
secretase activities are increasingly well characterized: β-site APP cleav-
ing enzyme 1 (BACE1) accounts for almost all the β-secretase activity,
whereas a complex that includes presenilin 1 or 2 is responsible for the
γ-secretase activity (De Strooper, 2003). More recently, an additional
matrixine (MMP-MT5) has been shown to contribute to APP processing
by acting upstream of the β-site (Willem et al., 2015; Baranger et al.,
2016). Finally other N-terminal truncated Aβ peptide species can be gen-
erated by other proteases besides BACE1 (Wang et al., 2006; Schönherr et
al., 2016).
In contrast,α-secretase activity is lesswell characterized even if sev-
eral research groups have suggested that ADAM10 and ADAM17 are the
major enzymes responsible for constitutive and regulatedα-secretases-
mediated pathways in the brain (Lammich et al., 1999; Kuhn et al.,
2010). In addition to these direct cleavages taking place on APP, several
additional proteins are likely tomodulate APP levels by interferingwith
secretase activity, APP trafficking and/or APP degradation (Vincent and
Checler, 2012). This complex network of protein-protein interactions is
however poorly characterized and the identification of its components
should improve our understanding of APP biology and fate, and might
enable the delineation of therapeutic approaches.
Given this context, we decided to focus on ADAMs and related pro-
teins. Our study was inspired by several observations besides our knowl-
edge of the involvement of ADAMs asα-secretases (Rosenberg, 2009): (i)
ADAMs and APP are involved in many different biological processes in-
cluding brain development, plasticity and repair (Yang et al., 2006), and
(ii) several matrix metalloproteases (MMP-2, -3 and -9) can degrade Aβ
peptides (White et al., 2006; Reitz et al., 2010; Carson and Turner,
2002).We therefore performed amulti-angle screen for newcomponents
of APP metabolism, with a focus on MMPs, ADAMs and related proteins.
We postulated that differentially expressed MMPs, ADAMs and related
proteins (when comparing expression in Alzheimer's disease brains and
control brains) might be clues for their involvement in APP physiology.
2. Materials and Methods
Written informed consent was obtained from study participants or,
for those with substantial cognitive impairment, from a caregiver,legal guardian, or other proxy and the study protocols for all popula-
tions were reviewed and approved by the appropriate Institutional re-
view boards of each country.
All animal experiments were approved by the local animal care and
use committee (Comité d'Ethique en Experimentation Animale du Nord -
Pas de Calais, Lille, France).
2.1. Study Design
We postulated that uncharacterized MMPS, ADAMs or related pro-
teins may be involved in the APP metabolism. The purpose of this
study was thus to explore this possibility. Potential candidates were se-
lected from transcriptomic analyses targetingMMPs/ADAMsexpression
using total RNAs extracted from the brain of AD cases and controls. The
strongest variations in expression were validated in an independent
sample of brains using a different technology. Potential correlation be-
tween amyloid deposition in the brain of AD cases and expression of
our genes of interest were examined. This work allowed us to select
ADAM30 for further exploration.
We developed ADAM30 over- or under-expression experiments in
different cellular models to assess ADAM30 impact on the APP metabo-
lism. Potential α-, β- or γ-secretase activities of ADAM30 were exam-
ined. A without a priori research for ADAM30 substrates was
performed using COFRADIC experiments. Impact of ADAM30 on APP
metabolism through CTSD activation was tested using pharmacological
or siRNA tools. All the experiments have beenmade at least in triplicates
and by two independent manipulators for most of them. This work
allowed us to demonstrate that ADAM30 modulates the APP metabo-
lism through CTSD activity.
The in vitro observations were finally extended to an “Alzheimer-
like” transgenic mouse model specifically over-expressing ADAM30 in
neurons. Primary cultures of adult neuronswere used to validate the re-
sults obtained from cell lines. Measurement of soluble Aβ42 and amy-
loid deposition were performed to corroborate the in vitro results in
the mouse brains. Electrophysiological analyses were finally performed
to extend the results to neuronal activity. All the analyses were per-
formed in a blinded fashion. Our data demonstrated that ADAM30
over-expression led to a decrease in Aβ42 secretion in primary cultures,
in soluble Aβ42 and amyloid deposition in the cerebral tissue and to a
rescue of LTP in the Alzheimer-like mouse brain.
2.2. Microarray Analyses
The preparation of human brain samples is described in the Supple-
mentary experimental procedures. Total RNAwas extractedwith a phe-
nol/chloroform protocol (TRIzol® reagent, Invitrogen®, USA) from
frozen frontal cortex brain tissue from one hundred fourteen
Alzheimer's disease samples and one hundred sixty seven control sam-
ples. The quality of the total RNA extract was assessed with an Agilent
2100 Bioanalyzer (Agilent) and the ribosomal 28S/18S RNA ratio was
estimated with the system's onboard biosizing software. Twelve
Alzheimer's disease cases and twelve controls were selected among
the initial samples by applying the following two criteria: (i) a ribosom-
al 28S/18S RNA ratio of 1.0 or more; (ii) a Braak stage below 2 (for con-
trol samples) (Table S1) (Bensemain et al., 2009).
Specific oligonucleotides for one hundred thirty two open reading
frames (corresponding to MMPs, ADAMs, ADAMTSs and related pro-
teins) were designed using OLIGOMER software (Mediagen) (Supple-
mentary experimental procedures and Table S2; Bensemain et al.,
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population that was homogeneous in terms of length (Sigma-Aldrich®,
Germany). All oligonucleotideswere 5′-functionalizedwith a C6H12NH2
arm.
In order to decrease the potential influence of inter-individual vari-
ability in the control population, we compared the genetic expression
of each Alzheimer's disease case with the pool of control samples (see
the Supplementary experimental procedures). Complementary RNA
corresponding to 10 μg of the initialmRNA extractwas produced by am-
plification and labeled with a Cy5 or Cy3 fluorophore using a Fluores-
cent Linear Amplification Kit® (Agilent), according to the
manufacturer's instructions. After hybridization, microarrays were ana-
lyzed as described previously (Bensemain et al., 2009, see the Supple-
mentary experimental procedures). It is important to note that the
analyses of the one hundred thirty two ADAMs, MMPs and related pro-
teins were performed with a one thousand seven hundred seventy one
gene microarray used in a previous project in our laboratory
(Bensemain et al., 2009; Chapuis et al., 2009). Accordingly, the thresh-
old for statistical significance was set to p b 10−5 (after Bonferroni cor-
rection), in order to select genes differentially expressed in the
Alzheimer's disease brain.
2.3. Quantification of ADAM17, ADAM30, ADAM33 and ADAMTS16mRNAs
Total RNA samples (from forty two controls and fifty one
Alzheimer's disease cases)were randomly selected (see Supplementary
material section) from among the samples not used in the
transcriptomic experiments. Levels of ADAM17, ADAM30, ADAM33
and ADAMTS16 mRNAs were quantified as described by the supplier
(Quantigene®, Panomics) (Canales et al., 2006), normalized against
two different housekeeping genes (β-actin and β-glucuronidase: see
the Supplementary material procedures) and were expressed in arbi-
trary units (AU). Comparisons were performed with a Mann-Whitney
non-parametric test.
2.4. Immunohistochemistry Experiments
The brains used for immunohistochemistry (IHC) experiments were
obtained at autopsy (at Lille University Medical Center) from Caucasian
patients suffering fromAlzheimer's disease and fromCaucasian controls
in whom the absence of Alzheimer's disease had been confirmed
neuropathologically. These sampleswere not used in the transcriptomic
experiments. In all patient samples, the neuropathologic features of
Alzheimer's disease were confirmed by IHC and Western blot analysis
of Tau, Aβ and α-synuclein (Delacourte et al., 2002). Brain samples
were fixed in formalin for brightfield microscopy. Paraffin sections
from the anterior frontal cortex (Brodmann area 10) were processed
in an automatic Benchmark-XT system (Ventana, USA). Polyclonal anti-
bodies against a sixteen-amino acid polypeptide within the human
ADAM30 protein (Table S3) were raised according to a standard proto-
col (with three months of immunization, Interchim®, France). Anti-
ADAM30 antibody and pre-immune rabbit serum (both diluted at
1:500) were applied after sample heating and were revealed using a
standard immunoperoxidase technique.
2.5. Analyses of APPMetabolism as a Function of ADAM30WT or ADAM30mut
Expression
Plasmid constructions are fully described in the Supplementary ex-
perimental procedures.
SKNSH-SY5Y-APP695WT and HEK293/HEK293-APP695WT cell lines
were respectively cultured in DMEM and DEM/F12 supplemented
with 10% serum FCS, 2 mM L-glutamine, 50 U/ml penicillin, 50 μg/ml
streptomycin and (for SKNSH-SY5Y-APP695WT only) 1% MEM NEAA
(Invitrogen®, USA) at 37 °C in a humidified atmosphere with 5% CO2.For the analysis of APP metabolism, SKNSH-SY5Y-APP695WT and
HEK-APP695WT cell lines (300,000 cells per well at seeding) were
transfected with pcDNA-Mock, pcDNA-ADAM30WT, pcDNA-ADAM30-
mut, shRNA pU6/ADAM30 vectors (500 μg) or siADAM30 (ON-
TARGETplus ADAM30 siRNA, GE Dharmacon). Transient transfection
was performed using an Exgen500 protocol (Fermentas®, France) in
SKNSH-SY5Y-APP695WT cells and a Fugene-HD protocol (Roche Diag-
nostics®, Switzerland) in HEK/HEK-APP695WT cells, according to the re-
spective manufacturers' instructions. SiADAM30 were specifically
transfected using Lipofectamine RNAi Max. Of note, because of the low
endogenous level of ADAM30 expression, shRNA and siRNA targeting
ADAM30 were first validated in SKNSH-SY5Y stably over-expressing
ADAM30 (Fig. S12).
Forty-eight hours after transfection, supernatants were collected for
the quantification of APP by-products and cells were lysed to assay for
expression of ADAM30WT/mut or endogenous ADAM30 byWestern blot-
ting. Aβ1–40, Aβ1–42, sAPPα and sAPPβ were measured in sandwich
ELISAs (INNOTEST® β-amyloid (1–42) and β-amyloid (1–40),
Innogenetics, Ghent, Belgium), and the sAPPα and sAPPβ Assay kits
(IBL-International®, Germany), according to the respective manufac-
turers' recommendations. Three independent, duplicate experiments
were carried out for each mutant and measurements were performed
twice for each sample.
For the BACE1 fluorometric assay, HEK293 cells were transfected
with ADAM30WT/mut cDNAs. Forty-eight hours after transfection, cells
were pipette-lysed with 50 μl of Tris-HCl (10 mM, pH 7.5) and moni-
tored for BACE1 activity, as described previously (Andrau et al., 2003).
For the γ-secretase activity assay, solubilized membranes were obtain-
ed from intact HEK293 cells transfectedwithADAM30WT/mut cDNAs and
analyzed as described previously (Sevalle et al., 2009).
For analyses of APPΔC8, APPF690S and APPE691V metabolism,
HEK293 cell lines (300,000 cells per well at seeding) were transfected
with pcDNA-Mock or pcDNA-ADAM30WT (250 μg) and pcDNA-
APP695WT, pcDNA-APPΔC8, pcDNA-APPF690S or pcDNA-APPE691V
(250 μg). Three independent, duplicate experiments were carried out
for each mutant and all measurements were performed twice for each
sample.
2.6. Identification of ADAM30 Substrates
Two HEK293-APP695WT cell lines stably overexpressing ADAM30WT
or ADAM30mut (HEK293-ADAM30WT and HEK293-ADAM30mut) were
generated (as mentioned above, one advantage of the HEK293 cell
line is the absence of endogenous ADAM30 expression; see the Supple-
mentary experimental procedures). These HEK293 cell lines were used
to perform a targeted COFRADIC analysis of N-terminal peptides in a
highly complex mixture, whereas all internal peptides were
disregarded. The combination of COFRADIC, SILAC and N-terminal tag-
ging chemistries generates quantitative data on the modification status
of the N termini of the proteins present in the mixture. This approach
provides an overall profile of enzyme activities and substrates (Staes
et al., 2011; see the Supplementary experimental procedures).
For the CTSD assay, recombinant ADAM30WT and ADAM30mut were
generated by Genscript (Piscataway, USA) (see the Supplementary ex-
perimental procedures). The activity of recombinant human CTSD
(R&D Systems, Lille, France)wasmeasured via cleavage of a fluorogenic
peptide substrate (Mca-PLGL-Dpa-AR-NH2 from R&D Systems). CTSD
(16 μg/ml) was pre-incubated at 37 °C for 30 min before being diluted
eight-fold into 50mMTris-HCl, pH 7.5 buffer with 300mMNaCl. Twen-
ty-five microliter aliquots of enzyme sample were transferred into the
wells of black 96-well microplates (Corning, Amsterdam, The Nether-
lands) and incubated with substrate at 37 °C for 40 min. The final vol-
ume of the incubation solution was 100 μl and the final reagent
concentrations were 0.5 μg/ml of CTSD and 10 μM of substrate in assay
buffer (0.1 M sodium acetate and 0.2 M NaCl, pH 3.5). Fluorescence
was measured using a Victor3 V1420 plate reader (Perkin Elmer,
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emission filter. The fluorescence of substrate blanks was subtracted. To
evaluate the effect of ADAM30WT or ADAM30mut on CTSD activity, CTSD
was pre-incubated with 84 μg/ml of each protein prior to dilution and
substrate addition. The observed CTSD activities were compared with
that measured when CTSD was pre-incubated with 84 μg/ml of bovine
serum albumin (Sigma, Lyon, France).
For measuring intracellular CTSD activity, the SKNSH-SY5Y-
APP695WT and HEK-APP695WT cell lines (300,000 cells per well at
seeding) were transfected with pcDNA-Mock, pcDNA-ADAM30WT or
pcDNA-ADAM30mut vectors. After 48 h, cells were lysed and the time
course of CTSD activity (0, 5, 10 and 15min)was monitored using a flu-
orometric SensoLyte® Cathepsin D assay (AnaSpec®, USA).
For the cathepsin inhibition experiments, HEK-APP695WT cell lines
were transfected for 24 h with pcDNA-Mock, pcDNA-ADAM30WT or
pcDNA-ADAM30mut vectors and then exposed for 24 h to pepstatin A
(10 μM; Sigma-Aldrich, Germany), leupeptin (10 μM; Sigma-Aldrich,
Germany) or E64-D (1 μM; Sigma-Aldrich).
Transient Co-transfection of CTSD siRNA (37.5 pmol ~0.75 μg, ON-
TARGETplus CTSD siRNA, GE Dharmacon) and pCDNA3.1-ADAM30 vec-
tor (1.25 μg of DNA per well) was performed using Lipofectamine®
2000 Transfection Reagent (ThermoFisher Scientific) according to the
manufacturer's recommendations. After 36 h of transfection and 24 h
of secretion (wash after 12 h of transfection), cells were finally lysed
and supernatants were recovered. Cell extracts were analyzed by west-
ern blot to validate both ADAM30WT over-expression and CSTD under-
expression.
By-products of APP metabolism were then quantified as previously
described. Three independent duplicate/triplicate experiments were
carried out and measurements were performed twice for each sample.
2.7. Western Blot
Antibody against CTSD was diluted at 1/5000. The primary antibod-
ies used to detect ADAM30 were diluted at 1/1000. The antibody 6E10
was used for APP detection at 1/5000. A monoclonal mouse antibody
was used to detect β-actin at 1/10000. Antibody references are indicat-
ed in Table S3. Immunoreactive complexes were revealed using the ECL
™Western Blotting kit (Amersham®).Membraneswere digitized using
the ChemiDoc MP System (Bio-Rad, Marnes-la-Coquette, France).
2.8. Immunofluorescence and PLAs
The SKNSH-SY5Y-APP695WT cell line was cultured on poly-L-Lys-
coated glass coverslips (Lab-Tek® Chamber Slide System 2 wells,
Nunc, Roskilde, Denmark) for 24 h. The cells were then transfected
with pcDNA-ADAM30WT-GFP, pcDNA-ADAM30mut-GFP, pcDNA-
ADAM30WT or pcDNA-ADAM30mut vectors. After 48 h, cells were fixed
in PBS containing 4%paraformaldehyde for 20min at room temperature
and further permeabilized with 0.25% (v/v) Triton X-100 in PBS. After
blocking in 5% (w/v) BSA, fixed materials were incubated overnight at
4 °C with primary antibodies (diluted 1/500 in PBS supplemented
with 5% (w/v) BSA and 0.25% Triton X-100.). After washing, appropriate
secondary antibodies were used (diluted 1/400). Primary and second-
ary antibody combinations are described in Supplementary Table 3.
The slides were read under a confocal microscope (Leica LSM 710) at
the MICPAL microscopy facility at the Pasteur Institute of Lille (Lille,
France).
For the PLAs, cells were washed with PBS and then fixed in PBS con-
taining 4% paraformaldehyde for 30 min at room temperature. Cells
were permeabilized with 0.25% Triton X-100 in PBS for 10 min. After
blocking in 1% bovine serum albumin (BSA), cells were incubated for
2 h at room temperature with primary antibodies diluted in 1% BSA in
PBS. The anti-CTSD antibody (Abcam, catalog number ab6313-100)
was diluted 1/100 and the anti-ADAM30 antibody (Genetex, catalog
number GTX117694) was diluted 1/50. Cells were then washed threetimes in PBS. All reagents used in the PLAs were purchased from Olink
Bioscience (Uppsala, Sweden). The PLAs were performed according to
the manufacturer's instructions by using anti-CTSD and anti-ADAM30
as primary antibodies.2.9. Transgenic Mouse Experiments
2.9.1. Mouse Models
Two conditional ADAM30floxstopflox and ADAM30mutfloxstopflox trans-
genicmicewere generatedwithin a C57Bl6Nbackground (Taconic, Ger-
many). In brief, a construct containing the GAGGS promoter, a LoxP-
NeomycineStop-LoxP cassette and the humanAdam30WT or Adam30mut
gene was introduced In the Rosa26 locus. CamKIIα/Cre mice (in which
Cre gene expression is driven by the CamKIIα promoter (Tsien et al.,
1996) and hAPPswe,Ind mice expressing a human APP gene bearing
Swedish (670/671KM-NL) and Indiana (717 V-F) mutations were ob-
tained from The Jackson Laboratory (Mucke et al., 2000). Both mice
have a C57Bl6J background. The first cross was between hAPPswe,Ind
mice and CamKIIα-Cre mice, yielding APP+/−/Cre+/−mice. The second
cross was between APP+/−Cre+/−mice and hADAM30floxstopflox+/− or
hADAM30mutfloxstopflox+/− mice, yielding triple transgenic hADAM30-
WTΔstop-hAPPswe,Ind-Cre or hADAM30mutΔstop-hAPP-Cre mice expressing
ADAM30 or ADAM30mut in their brains. The mice data were systemati-
cally obtained from a crossing of a hADAM30floxstopflox+/− heterozygous
C57BL6N female with an APP+/−Cre+/− heterozygous C57BL6J male
without any backcross. So the genetic background has been systemati-
cally controlled and the phenotypes were analyzed only at the first
generation.
All the mice were genotyped by PCR using genomic DNA isolated
from tail tips, according to the provider's protocols (The Jackson Labora-
tory; Table S4 and Fig. S13), Mice were maintained on a standard diet
with ad libitum access to water in a specific pathogen-free animal facil-
ity. The mice were studied at the age of 10 months ± 1 week. At sacri-
fice, the brains were removed. After sagittal section, one hemibrain
was used for histological studies and the other was sectioned on brain
matrices to isolate the cortices and hippocampi, whichwere then stored
at−80 °C.2.9.2. Aβ42 Peptide Assays
Following the validation of gene expression in the brain (see the
Supplementary experimental procedures), snap-frozen hippocampi
were homogenized in guanidine buffer (Johnson-Wood et al., 1997).
Hippocampal levels of Aβ42 were quantified with commercially avail-
able ELISA kits (Innogenetics kit for Aβ42). The protein concentration
in hippocampal extracts was determined using a Bradford assay kit
(Bio-Rad Laboratories).2.9.3. Measurements of CTSD Activity Ex Vivo
Cortex samples were homogenized with dithiothreitol-containing
assay buffer from the SensoLyte 520 Cathepsin D assay kit (AnaSpec®,
USA), using a high-power homogenizer. After centrifugation for
10 min at 12,000 rpm and 4 °C, supernatants were assayed for CTSD
with the SensoLyte® Cathepsin D assay kit (AnaSpec®), according to
the manufacturer's instructions. The CTSD activity was measured inde-
pendently in two different experiments: a time-course measurement
every 5min between 0min and 30min and an end-point measurement
at 30 min (Fig. 4). Each measurement was performed at least twice for
each cortex sample and the results were normalized against the sample
weight and protein concentration. At least three independent, duplicate
experiments were carried out and measurements were performed
twice for each sample. Comparisons were performed using a Mann-
Whitney non-parametric test (for the end-point experiment) or a
two-tailed t-test (for the time-course experiment).
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Hemibrains from APPsw,Ind, ADAM30WT/APPsw,Ind and ADAM30WT/
APPsw,Ind/Cre mice were processed by a high-throughput
neurohistological service (NeuroScience Associates). Briefly, hemibrains
were embedded in a green-colored solid matrix (Multibrain technolo-
gy) and cut along the rostrocaudal axis. For each brain, three sets of
30-μm-thick coronal sections (one hundred per set) were collected.
One set was used for Aβ-peptide IHC experiments with a 6E10 mono-
clonal antibody and 3,3′-diaminobenzidine development. The other
two series were stored for further analysis. Block-face photographs
were taken (lateral resolution: 13 μm)before each sectionwas prepared
(Canon EOS 5D Mark III) (Dubois et al., 2007). Histology images were
digitized using a flatbed scanner (ImageScanner III, GE Healthcare)
with a lateral resolution of 5 μm.
2.9.5. 3D Reconstruction
All the image processing steps described below were performed
using the BrainRAT pipeline 3D-HAPi (Dubois et al., 2007, Dubois et
al., 2010; Vandenberghe et al., 2016) and a dedicated in-house image
processing software package (BrainVISA, http://brainvisa.info). All
image analyses were performed by operators blinded to the animal
group assignments (Fig. S14). For each brain, block-face photographs
and histological images were stacked. Brain tissue was automatically
segmented on block-face photography volumes and masked to remove
background. As block-face images were taken prior to sectioning at the
same position section after section, reconstructed photographic vol-
umes necessarily reflected the original shape of the frozen brains and
were used as a 3D reference. Affine registrations between two-dimen-
sional histological images and corresponding block-face photographs
were estimated and used to (i) correct for deformations due to histolog-
ical procedures and (ii) provide coherent histological volumes (xyz res-
olution: 5 × 5 × 90 μm3 for histological volumes stained with the 6E10
monoclonal antibody). For each animal, the block-face photography
volume and the corresponding IHC volume stainedwith 6E10monoclo-
nal antibodywere alignedwithin the same spatial reference framework.
2.9.6. Quantification of the Amyloid Load
Aβ peptide aggregates were segmented from the rest of the image
by applying a supervised Bayesian classifier (Chubb et al., 2006) to re-
constructed 6E10 IHC volumes. Each voxel was classified into either
positively stained amyloid plaques, non-stained tissue or background
as a function of the color intensities (red, green and blue) and the
mean neighborhood intensity (themean red, green and blue intensities
within the voxel's four-connected neighbors). A mouse hemibrain atlas
was derived from a publicly available, magnetic resonance imaging
(MRI)-based mouse brain atlas (http://www.mouseimaging.ca/
technologies/C57Bl6j_mouse_atlas.html) (Dorr et al., 2008) and regis-
tered on each photographic volume according to a protocol described
and validated elsewhere (Lebenberg et al., 2010). Briefly, non-linear
transformationswere estimated for each brain (usingMRI) and then ap-
plied to corresponding label atlas volumes. The percent volume occu-
pied by the 6E10 staining was computed for the forebrain as a whole
and the hippocampus in particular. Quality controls were performed vi-
sually for both registration and color segmentation processes. Compar-
isons between amyloid loads were performed with a Mann-Whitney
non-parametric test.
2.9.7. Electrophysiology Experiments
Mice were shipped to E-PHY-SCIENCE (Sophia-Antipolis, France). In
this study, twenty six 12-month-old transgenic mice (hADAM30WT-
hAPPSw,Ind-Cre, hADAM30WT-hAPPSw,Ind, hAPPSw,Ind) and 8 WT mice
were used. In total thirty four mice were scarified for the study. Of
note, premature death is a phenotype of transgenic Alzheimer mice
and no mice were lost in any of the groups during the course of the
study. Acute slices (400 μm thick) were prepared with a vibratome
(VT 1000S; Leica Microsystems, Bannockburn, IL) in ice-cold gassedaCSF enriched with sucrose. Sections were incubated in aCSF supple-
mented at 34 °C for 20 min and then kept at room temperature for at
least 1 h before recording.
Recording was performed in a submerged chamber continuously
perfused with aCSF, at 1–2 ml/min. A monopolar electrode was placed
in the Schaffer collaterals, and stimulation was applied at 0.066 Hz
(every 20 s) with stimulus intensity ranging from 0 to 100 μA, yielding
evoked field EPSPs (fEPSPs) of 0–0.3 V.
fEPSPs were recorded in the stratum radiatum using a borosilicate
micropipette filled with aCSF.
The signal was amplifiedwith an Axopatch 200B amplifier (Molecu-
lar Devices, Union City, CA), digitized by a Digidata 1200 interface (Mo-
lecular Devices) and sampled at 10 kHz with Clampex 10 (Molecular
Devices). aCSF, during incubation and recording, was composed of the
following (in mM): 119 NaCl, 11 D-glucose, 1.3 MgCl2·6H2O, 1.3
NaH2PO4, 2.5 KCl, 2.5 CaCl2, 26 NaHCO3, gassed with O2/CO2 (95/5%)
at least 20 min before use and throughout the experiment. Baseline
was recorded for a minimum of 20 min or until stable. LTP was induced
by stimulationwith 100Hzwith four trains of a 1-s tetanus separated by
20 s.
Recordings were acquired using Clampex (Molecular Devices) and
analyzed with Clampfit (Molecular Devices). Experimenters were
blinded to treatment for all experiments. One or more slices from each
mouse were used and were averaged, so that animals and not slices
are considered biological replicates. Data were analyzed by measuring
the slope of individual fEPSPs at 1–1.5ms after the stimulus pulse by lin-
ear fitting using Clampfit (Molecular Devices).
3. Statistical Analyses
Statistical analysis was performed using SAS statistical software
(version 9.1, SAS Institute Inc., Cary, NC, USA).
4. Results
4.1. Transcriptomic Analyses Show That ADAM30 is Under-expressed in AD
Brains
Using total RNA from the frontal cortex of twelve Alzheimer's dis-
ease cases and twelve healthy controls, we performed a transcriptomic
analysis of one hundred thirty two genes coding for MMPs, ADAMs and
related proteins (the complete results are provided in Table S2). Four
ADAMs were found to be differentially expressed in the brain of
Alzheimer's disease cases compared with controls (ADAM17,
ADAM33, ADAMTS16 over-expressed and ADAM30 underexpressed;
p b 1 × 10−5 for all comparisons after Bonferroni correction; see the
Materials and Methods section and in Bensemain et al. (2009)). Of
note, since the analyses of the 132 ADAMs, MMPs and related proteins
were performed using a 2741-gene homemade microarray (see again
the Materials and Methods section and in Bensemain et al. (2009),
this design allowed us to determine whether the decrease in ADAM30
expression may be imputed to neuronal death. In order to evaluate
this potential bias, we compared the expression of a subset of genes re-
ported as only expressed in neuron (n = 113) to genes not exclusively
(or not) expressed in neurons (n= 1789). Importantly, we did not ob-
serve any significant differences in terms of fold-change (Fig. S1). To by-
pass inherent risks of false positives in such systematic transcriptomic
approaches despite of multiple testing corrections, the expression
level of these four ADAMs was then analyzed in an independent, larger
sample of AD cases (fifty one) and healthy controls (forty two).
ADAM30 underexpression (Fig. 1a) and ADAM33 overexpression were
confirmed whereas changes in the expression of ADAM17 and
ADAMTS16 genes could not be validated in this larger sample (Fig. S2).
Wefinally assessedwhether the levels of ADAM30/ADAM33 expres-
sion may be correlated with AD hallmarks in the brain. The decrease in
ADAM30 expression was significantly correlated with higher Aβ42
Fig. 1. Characterization of ADAM30 expression in the brain. (a) Expression levels of ADAM30 in the brains of Alzheimer's disease cases (fifty one) and controls (forty two). All values are
reported as arbitrary units (AU) following normalization against β-actin mRNA levels. All quantifications were carried out in triplicate in all individuals. The thick lines represent the
median ADAM30 expression level in cases and controls. The midline represents the mean value and the upper and lower horizontal lines represent the first and third quartiles,
respectively. Circles indicate individuals with extreme values (more than 2 SD above or below the mean value). p-Values refer to a Mann-Whitney non-parametric test. (b) Association
of Aβx-42 and Tau loads in the brain of Alzheimer's disease cases with the expression of ADAM30 (residual correction), normalized against the expression of a-actin housekeeping
gene. p values refer to Spearman's non-parametric test. (c) Immunohistochemistry experiments in human brain supporting ADAM30 expression in neurons. (d) A representative
experiment measuring transfection of a shRNA vector against ADAM30 into SKNSH-5Y5Y-APP695WT cells (ADAM30, and β-actin). (e) Mean differences (±SEM) in the amounts of
sAPPα, sAPPβ, A-1β40, A-1β42 in SKNSH-Sy5Y-APP695WT cells or (f) endogenous sAPPα, sAPPβ in SKNSH-SY5Y. Three independent experiments were performed in duplicate in
SKNSH-5Y5Y-APP695WT and in triplicate in SKNSH-SY5Y. *p b 0.05 (Mann-Whitney non-parametric test).
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1b and Fig. S3) while ADAM33 expression did not correlate with these
Alzheimer's disease markers (data not shown). Immunohistochemistry
experiments in human brain tissue revealed a neuronal expression of
ADAM30 (Fig. 1c and Fig. S4) as observed in a laser dissection
transcriptomic analysis (GSE15222 dataset described in Liang et al.
(2008)). We thus hypothesized that ADAM30 under-expression might
be harmful bymodulating Aβ peptide production and thus, we assessed
the putative involvement of ADAM30 in APP processing.4.2. ADAM30 Under-expression is Associated With Increased APP Catabo-
lites In Vitro
We first investigated whether modulation of ADAM30 expression
could be associated with an alteration of the APP metabolism in the
SKNSH-SY5Y cell line stably expressing the wild-type (WT) APP695 iso-
form (SKNSH-SY5Y-APP695WT). This model allows measuring the pro-
duction/secretion of all APP byproducts and quantifying separately
Aβ1–40 and Aβ1–42 peptides. ADAM30 under-expression (transient
284 F. Letronne et al. / EBioMedicine 9 (2016) 278–292transfection of SKNSH-SY5Y-APP695WT cells with a short hairpin RNA
(shRNA) targeting ADAM30; Fig. 1d)) increased the levels of all APP
products yielded by α-, β- and γ-secretases-mediated proteolysis and
particularly Aβ1–40 and Aβ1–42 (Fig. 1e). Both endogenous sAPPα and
sAPPβ secretionwere also increased in the SKNSH-SY5Y cells after tran-
sient transfection of ADAM30-shRNA (Fig. 1f) or of an ADAM30-siRNAs
(data not shown).
4.3. ADAM30 Catalytic Activity is Required for the Modulation of APP
Metabolism
ADAM30 holds a unique zinc-binding motif HEXXHXXGXXHD,
which is normally required for enzymatic activity (all metalloproteases
harbour a HEXXH motif and half of the ADAM proteins present such a
functional catalytic motif). We thus aimed at determining whether the
catalytic function of ADAM30 accounts for the observed modulation of
APP catabolites. To assess this possibility we generated mammalian ex-
pression vectors expressing either a wild-type ADAM30 (ADAM30WT)
or an ADAM30 with a mutated catalytic site (ADAM30mut, see Supple-
mentary information). These constructs were transfected either in the
SKNSH-SY5Y-APP695WT cell line or a HEK293 cell line also stably ex-
pressing the wild-type APP695 isoform (HEK293-APP695WT).
Over-expression of ADAM30WT in both cell lines triggers the exact
opposite effects observed when down-regulated ADAM30, i.e. de-
creased levels of all amyloidogenic and non-amyloidogenic APP catabo-
lites (Fig. 2A and 2B). This effect was not observed after overexpression
of catalytically silent ADAM30mut (Fig. 2a and b).
We next started evaluating pathways that could link ADAM30 and
APP catabolites. Strikingly, the fact that all APP catabolites were de-
creased by ADAM30 could have indicated that ADAM30 acted upstream
of secretases cleavages. One possibility could be that ADAM30 directly
modulates APP levels butwe showed that APPmRNA levelswere not af-
fected by ADAM30 modulation (Fig. S5). An alternative explanation
would be that ADAM30WT (but not ADAM30mut) modifies α-, β- and
γ-secretase activities. Since several ADAMs has been proposed as genu-
ine α-secretases, we first examined this possibility. However, ADAM30
did not exhibit α-secretase-like activity (Fig. S6a). Of note, ADAM30 is
not present at the membrane (Fig. S6b, c). We also ruled out ADAM30
as a modulator of β- and γ-secretases, since overexpression of WT or
mutated ADAM30 did not modify these activities (Fig. S7).
4.4. Identification of ADAM30 Substrates and Subsequent Targets
The above data suggest that ADAM30mightmodulate an intracellu-
lar pathway or an intermediate effector contributing to APP physiology.
Thus, we systematically searched for direct ADAM30 substrates or fur-
ther downstream targets by applying N-terminal combined fractional
diagonal chromatography (COFRADIC) (Staes et al., 2011) and compar-
ing the “stable isotope labeling with amino acids in cell culture”
(SILAC)-labeled N-terminones of HEK293 cells stably over-expressing
either WT or catalytically inactive ADAM30 (Fig. 2b). We identified
two thousand two hundred thirty eight proteins, eighteen of which
(characterized by twenty five distinct peptide sequences) had neo-N-
terminal peptides with higher intensities in cells over-expressing
ADAM30WT, suggesting a putative susceptibility to ADAM30-mediated
proteolysis (Fig. 2d). Most of these eighteen proteins were involved in
transcription and translation (e.g. histones and ribosomal proteins).
Even though the latter might well be substrates for ADAM30, we
suspected that this observation might reflect potential differentialFig. 2. Representative experiment measuring ADAM30WT and ADAM30mut overexpression in (
secreted amounts of sAPPα, sAPPβ, A1-β40 and A1-β42. Three independent experiments we
cell lines stably over-expressing ADAM30WT or ADAM30mut and cultured them in SILAC me
amounts of proteins from the two samples were mixed, conditioned and then analyzed in a
(characterized by twenty five distinct peptide sequences in COFRADIC) were significantly ov
cell line. (d) A representative mass spectrum of the neo N-terminal peptide of CTSD (ALGGV
cell line (mutant cell line), whereas the peptide with mass m/z 512,82 Da originates from the 1extraction of proteins, e.g. potential differences in cell growth between
HEK293-ADAM30WT and HEK293-ADAM30mut cell lines. After
discarding all proteins linked to transcription and translation, only
three peptides (and thus proteins) showed different ratios: insulin re-
ceptor substrate 4 (IRS4), cathepsin D (CTSD) and G kinase-anchoring
protein 1 (GKAP1). We decided to focus on CTSD (see representative
mass spectrum of the neo N-terminal peptide of CTSD, Fig. 2e). Indeed,
the potential ADAM30 cleavage site identified in the COFRADIC experi-
ment matched the CTSD endoproteolysis domain (residues 161–169)
leading to a mature, active, lysosomal protease (Fig. 3A) (Benes et al.,
2008). This latter observation suggests that ADAM30 acts as a CTSD
maturation enzyme leading to enhanced cellular activity.
4.5. CTSD Co-localizes With, and is Activated by ADAM30
To further investigate the hypothesis whereby ADAM30 targets
CTSD, we set up a fluorescence-based assay of CTSD activity. A human,
recombinant pro-CTSDwas incubatedwith its substrate in the presence
or absence of human recombinant ADAM30WT, ADAM30mut or bovine
serum albumin (BSA). Incubation with ADAM30WT increased CTSD ac-
tivity, whereas this effect was not detected after incubation with either
ADAM30mut or BSA (Fig. 3b). In native SKNSH-SY5Y and transiently
transfected HEK293-APP695WT cells, proximity ligand assay (PLA) re-
vealed that respectively endogenous and overexpressed ADAM30WT
co-localized with endogenous CTSD (Fig. 3c). Overexpression of
ADAM30WT (but not ADAM30mut) was consistently associatedwith ele-
vated CTSD activity in transiently transfected HEK293-APP695WT cells
(Fig. 3d) or SKNSH-SY5Y-APP695WT cells (Fig. 3e). Inversely, transfection
of ADAM30-siRNA led to a decrease in CTSD activity in native SKNSH-
SY5Y cells (Fig. 3f). Of note, mutagenesis of ADAM30mut did not appear
to alter the protein compartmentalization when compared with the
main localization of ADAM30WT in late-endosome (Fig. S8).
4.6. CTSD Activity is Required for the Modulation of APP Metabolism by
ADAM30
Both ADAM30's cellular localization and its ability to increase CTSD
activity led us to postulate that ADAM30WT could contribute to the lyso-
somal CTSD maturation/activation and thereby, could favor APP degra-
dation. This hypothesis may explain our observation of a general
decrease in amyloidogenic and non amyloidogenic APP catabolites and
agrees with our empirical observation that exposure to generic lyso-
some inhibitors (e.g. bafilomycin A1 and chloroquinone) abolished
ADAM30WT-mediated impact on cellular APP metabolism (Fig. S9).
We further investigated this hypothesis by testing the impact of dif-
ferent pharmacological inhibitors: pepstatin (an aspartyl protease in-
hibitor with activity mainly directed towards CTSD), leupeptin (a
serine and cysteine proteinase inhibitor with selective activity against
cathepsin B) and E64D (a cysteine proteinase inhibitor that targets
CTSB, cathepsin L and calpain). In the presence of pepstatin, the effect
of ADAM30WT expression in HEK293 cells was no longer detected (Fig.
4a). In contrast, leupeptin (a serine and cysteine proteinase inhibitor
with selective activity against CTSB) did not alter the impact of
ADAM30WT expression on APP metabolism in HEK293-APP695WT cells
(Fig. 4a). Similar results were obtained with E64D (Fig. 4a). Pepstatin
could have elicited non-specific effect on the APP metabolism. In order
to confirm themolecular cascade linking ADAM30, CTSD and APP, we fi-
nally down-regulated CTSD expression with a siRNA targeting CTSD in
HEK293 cells over-expressing or not ADAM30WT. When CTSD wasa) SKNSH-5Y5Y-APP695WT and (b) HEK-APP695WT and mean differences (±SEM) in the
re performed in duplicate. *p b 0.05 (Mann-Whitney non-parametric test). (c) HEK293
dium supplemented with 12C- or 13C-labeled arginine, respectively. After lysis, equal
two-step HPLC process (see the Materials and Methods section). (c) Eighteen proteins
er-represented in the HEK293-ADAM30WT cell line, relative to the HEK293-ADAM30mut
KVER). The peptide with mass m/z 509,81 Da originates from the 12C6 arginine-labeled
3C6 arginine-labeled cell line (WT cell line).
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Fig. 3. Characterization of CTSD activation by ADAM30. (a) Proteolysis of the pro-CTSD for CTSD activation. The black arrow shows the cleavage site for ADAM30 between amino acids 167
and 168 (corresponding to the activational processing of CTSD). (b) In vitromeasurement of CTSD activity (mean± SD) after incubation of recombinant BSA, ADAM30WT or ADAM30mut
with a CTSD peptide substrate. (c) Proximity ligation assay with human endogenous ADAM30WT and CTSD proteins in native SKNSH-SY5Y and with overexpressed ADAM30WT and
endogenous CTSD in HEK293 cells. CTSD activity in HEK293-APP695WT (d) or SKNSH-SY5Y-APP695WT (e) cells transfected with ADAM30WT, ADAM30mut or empty vector (Mock). The
CTSD activity was assayed in three independent experiments, with a measurement every at 5, 10 and 15 min (means ± SEM). Top-right: representative kinetic experiment. (f) CTSD
activity in SKNSH-SY5Y cells transfected with ADAM30-siRNA. The CTSD activity was assayed in three independent experiments, with a measurement every at 5, 10 and 15 min
(means ± SEM). Top-right: representative kinetic experiment. *p b 0.05 (Mann-Whitney non-parametric test). Three independent experiments were performed in duplicate.
286 F. Letronne et al. / EBioMedicine 9 (2016) 278–292down-regulated, the effect of ADAM30WT expression in HEK293 cells
was again no longer detected (Fig. 4b).
Altogether, these results strongly suggested that ADAM30 might be
involved in APP degradation via selective activation of lysosomal
CTSD. In line with our previous results, it is noteworthy that in a
HEK293 cell line stably overexpressing APP695WT andADAM30WT, expo-
sure to pepstatinwas also associatedwith a 51% increase in intracellularAPP accumulation (relative to cells not overexpressing ADAM30WT;
p b 0.01; Fig. 4c).
4.7. Lysosome Sorting of ADAM30 is Required for its Modulation of APP
We finally assessed whether the consensus sequences for lysosomal
sorting in the APP C-terminal tail (Lai et al., 1995; Kouchi et al., 1998;
287F. Letronne et al. / EBioMedicine 9 (2016) 278–292Kouchi et al., 1999) was required for ADAM30WT impact on APPmetab-
olism. In a first step, we mutated lysine 688 of APP695WT into a stop
codon (APPΔC8) (Fig. 4d); this leads to deletion of the last eight C-ter-
minal amino acids (the lysosome-addressing sequence YKFF, corre-
sponding to YXXØ, where Ø is a highly hydrophobic residue) but does
not modify the sequence controlling APP endocytosis. Fig. 4e showsFig. 4. Assessment of the impact of ADAM30 on the APP metabolism through CTSD activation. (
transfection with ADAM30WT or mock vector. Cells were treated for 24 h at the indicated conce
are shown. (b) Impact of CTSD inhibition by siRNA on APPmetabolism according to ADAM30WT
A1β-42 are shown. (c) The impact of inhibiting APP degradation inHEK293-APP695WT-ADAM3
leupeptin at the indicated concentration. Intracellular APP accumulation was assessed using im
bar: 100 μm. The graph represents the mean difference (±SEM) in fluorescence intensity p
different mutation used in the C-ter APP. (e) The impact of ADAM30 overexpression on th
secreted amounts of sAPPα, sAPPβ, Aβ1–40, and Αβ1–42 are shown. In all panels, three ind
(Mann-Whitney non-parametric test).that the transient co-expression of APPΔC8 and ADAM30WT in
HEK293 cells abolished the decrease in APP catabolites associated
with ADAM30WT expression. Further, we mutated phenylalanine at po-
sition 690 (APPF690S) into a serine residuewithin the lysosome-address-
ing sequence. Fig. 4e also shows that transient co-expression of APPF690S
and ADAM30WT in HEK293 cells abolished the decrease in APP productsa) Impact of pepstatin, leupeptin or E64D treatment in HEK293-APP695WT cells 48 h after
ntration. Mean differences (±SEM) in the amounts of sAPPα, sAPPβ, Aβ1–40 and A-1β42
over-expression. Mean differences (±SEM) in the amounts of sAPPα, sAPPβ, Aβ1–40 and
0WT cells. APP degradationwas blocked by 24 h of treatmentwith bafilomycin, pepstatin or
munofluorescence staining with LN27 antibody against the N-terminal part of APP. Scale
er cell (n N 150) for the indicated concentration. (d) Schematic representation of the
e metabolism of C-ter-mutated APP in HEK293 cells. Mean differences (±SEM) in the
ependent experiments were performed in duplicate after 24 h of transfection. *p b 0.05
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acid 691 (outside the lysosome-addressing sequence) into a valine
(APPE691V), did notmodify ADAM30wild-type phenotype. These results
thus indicate that only a mutation within the lysosome addressing se-
quence (APPF690S) abolished ADAM30-mediated impact on APPmetab-
olism. Of note, we did not detect any modification on APPWT
endocytosis in line with ADAM30WT over-expression (data not shown).
4.8. Overexpression of ADAM30 Modulates Aβ Production and Deposition
In Vivo
To corroborate our observations in vivo and further evaluate the im-
pact of ADAM30 on Aβ peptide secretion and amyloidosis, we sought to
generate a transgenic mouse model. It was not possible to develop
ADAM30 knock-out mice (ADAM30 is not expressed in the mouse
brain (Allen Brain Atlas, http://www.brain-map.org and our data, Fig.
5a and Supplementary Fig. 13) contrary to what we observed in
humans. We thus generated APPSw,Ind mice that conditionally
overexpressed hADAM30WT in the neurons of the forebrain (as previ-
ously mentioned, immunohistochemistry experiments were consistent
with the expression of human ADAM30 in neurons in human brain tis-
sue (Fig. 1c)). Primary cultures of adult neurons indicated that expres-
sion of ADAM30WT was only observed in neurons generated fromFig. 5. Impact of ADAM30 over-expression in neurons and AD-like models on Aβ secretion and
mouse hippocampus (n= 3). (b) Mean differences (±SEM) in the secreted amounts of sAPPα
Three independent experiments were performed in duplicate. *p b 0.05 (Mann-Whitney non-
hippocampi of different transgenic mice overexpressing ADAM30WT/mut or not. The thick lin
upper and lower horizontal lines represent the first and third quartiles, respectively. Circles in
p-Values refer to a Mann-Whitney non-parametric test. (d) Differences in CTSD activity in the
represent the median CTSD activity level. The midline represents the mean value and the upp
indicate individuals with extreme values (more than 2 SD above or below the mean value). p-hADAM30WT-hAPPSw,Ind-Cre mice (Fig. 5a). As observed in cell lines, a
decrease in APP catabolites was also observed in primary cultures of
adult neurons expressing ADAM30WT (Fig. 5b).
We then extended our results by analyzing the level of soluble
Aβ42 in the mouse hippocampus. We observed significantly lower
hippocampal levels of soluble Aβ42 upon induction in mice overex-
pressing hADAM30WT (−39%, relative to hADAM30WT-hAPPSw,Ind
mice; p = 0.03). We also generated mice that conditionally
overexpressed hADAM30mut in order to confirm that ADAM30-me-
diated potential effects are genuinely linked to its catalytic activity.
Remarkably, we did not detect any lower levels of soluble Aβ42 in
these mice overexpressing hADAM30mut (Fig. 5c). CTSD activity
was also significantly higher in the cortex of mice overexpressing
hADAM30WT (but not in those overexpressing hADAM30mut) than
in hADAM30-hAPPSw,Ind mice (+34%, p b 0.0001, and +7%, p =
0.82, respectively; Fig. 5D). Interestingly, we also observed a nega-
tive correlation between CTSD activity and soluble Aβ42 concentra-
tions in hADAM30WT-hAPPSw,Ind-Cre mice (p b 0.05 in Spearman's
correlation test, Fig. S10).
All these observations are in full accordance with our in vitro data
and support the claim that our observed effects are indeed specifically
due to ADAM30 enzymatic activity. Furthermore, our results support a
direct link between ADAM30, CTSD activation and amyloid load.CTSD activity. (a) ADAM30 expression at the protein level in adult neurons from 2 month
, sAPPβ, and Aβ1–42 in adult neurons (Div 19) according to ADAM30WT over-expression.
parametric test). (c) Differences in levels of soluble Aβ1–42 peptide concentration in the
es represent the median Aβ1–42 level. The midline represents the mean value and the
dicate individuals with extreme values (more than 2 SD above or below the mean value).
cortex of different transgenic mice overexpressing ADAM30WT/mut or not. The thick lines
er and lower horizontal lines represent the first and third quartiles, respectively. Circles
Values refer to a Mann-Whitney non-parametric test.
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throughput, three-dimensional (3D) histology method to determine
the Aβ load in mouse forebrain in general and the hippocampus in par-
ticular (see the Experimental procedures, Fig. 6a). Current standards for
the analysis of brain histopathological markers heavily rely on manual
intervention to delineate regions of interest and quantify the staining.
Data collection is thus usually restricted to a few tissue sections. As a
consequence, this approach allows avoiding eventual biases due to
low section sampling rate as demonstrated elsewhere (Vandenberghe
et al., 2016). By using this powerful approach, we observed that overex-
pression of hADAM30WT was associated with a 20% reduction in the Aβ
load (p = 0.03; Fig. 6b) in the mice forebrain. As expected, this reduc-
tion was also observed in analysis restricted to the hippocampus
(−28%, p = 0.01; Fig. 6c).Fig. 6. Impact of ADAM30 over-expression in AD-like models on Aβ loads. (a) Representative 2
Illustration in the same mice of the spatial distribution of 3D segmented Aβ peptide aggregates
APPsw,Ind transgenic mice overexpressing ADAM30WT or not. (c) The Aβ load in the hippocampu
The thick lines represent the median level. The midline represents the mean value and the up
indicate individuals with extreme values (more than 2 SD above or below the mean value). p-4.9. Overexpression of ADAM30 Partially Rescues LTP Deficits
Since APP catabolites have been shown to block hippocampal long
term potentiation (LTP) and impair learning function in mice
(Nalbantoglu et al., 1997), we aimed at establishing the functional im-
pact of hADAM30 overexpression on LTP in hAPPSw,Ind hippocampus.
Several paradigms of basal synaptic transmission were analyzed: maxi-
mum fEPSP slope, Maximum fEPSP amplitude, maximum fiber volley
amplitude and the function relating the stimulation intensity to fEPSP,
which is an index of basal synaptic strength. None of these parameters
were altered whatever the transgenic mice analyzed (Fig. 7a).
As expected, a LTP deficitwas observed in hAPPSw,Ind and hADAM30-
WT-hAPPSw,Ind mice and this deficit was partially restored over time in
hADAM30WT-hAPPSw,Ind-Cre mice (Fig. 7a and b). Mean fEPSP for theD sections and 3D reconstruction of the brains in mice overexpressing ADAM30WT or not.
corresponding to forebrain and hippocampus regions (b) The Aβ load in the forebrain of
s of APPsw,Ind transgenic mice overexpressing ADAM30WT or not. Box plots are as follows:
per and lower horizontal lines represent the first and third quartiles, respectively. Circles
Values refer to a Mann-Whitney non-parametric test.
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high frequency stimulation. A significant difference in LTPwas observed
between the hADAM30WT-hAPPSw,Ind-Cre mice and the other transgen-
ic mice in which no potentiation was observed. Even if ADAM30WT
over-expression did not fully rescue potentiation, an about 60% recov-
ery was observed (Fig. 7c).
5. Discussion
One of the main difficulties in differential expression analyses of
postmortem tissues relates to whether the variations detected are
causes or consequences of the disease process. By means of a multidis-
ciplinary approach involving various state-of-the-art techniques and
novel original transgenic mouse models, we identified ADAM30 as a
player in APP metabolism and show that its underexpression likely di-
rectly contributes to Alzheimer's disease physiopathology.
Very little is known about the physiological role of ADAM30
(Cerretti et al., 1999; Hu et al., 2009; Ho et al., 2013; Almawi et al.,Fig. 7. Impact of ADAM30WTover-expression on LTP inAlzheimer-likemousemodel. (a) LTP at t
in hADAM30WT-hAPPSw,Ind (ninemice) and hAPPSw,Ind ( eightmice) comparedwithWTmice (e
mice partially rescues LTP (nine mice). Inset graph shows input–output curves, which are com
hAPPSw,Ind-Cre (n = 9 mice), and WT mice (eight mice). (b) Traces show the field excitatory p
represent the average of baseline recording before 4 × 100-Hz stimulation, red traces show th
the percentage change in average fEPSP amplitude 40–60 min after 4 × 100-Hz stimulation. D2013; Gupta et al., 2012; Ellis et al., 2014), its putative involvement in
Alzheimer's disease and its protein partners. However, our results high-
light a new axis in APP metabolism, with APP sorting to lysosomes,
ADAM30-dependent CTSD activation and APP degradation. Overall,
this set of data supports previous mechanistically unsolved observa-
tions of an important lysosomal contribution to the metabolism of APP
(Funk and Kuret, 2012).
The potential APP degradation through ADAM30-dependent
CTSD activation could be either linked to the CTSD activity by itself
(CTSD was described to endoproteolyse the C100 APP fragment at
multiple sites and to display β-secretase-like activity, in vitro)
(Mackay et al., 1997; Chevallier et al., 1997) or to a CTSD-mediated
subsequent activation of other hydrolases (Benes et al., 2008). In
line with the recent description that PS1 mutations can be linked to
defective lysosomal proteolysis (Lee et al., 2010), our data support
the importance of the lysosome compartment in APP metabolism
and as a consequence in the Alzheimer's disease pathophysiological
processes.he CA3-CA1 synapses of hippocampal slices induced by 4× 100-Hz stimulation is impaired
ightmice). Cre dependent gene expression of hADAM30WT in hADAM30WT-hAPPSw,Ind-Cre
parable in hADAM30WT-hAPPSw,Ind (nine mice), hAPPSw,Ind (n = 8 mice), hADAM30WT-
ostsynaptic potential (fEPSP) from a representative animal from each group, black traces
e average over the last 20 min of post-stimulation recording. (c) Quantification indicating
ata are mean ± SEM. **p = 0.0005, **p = 0.0015 (Mann-Whitney non-parametric test).
291F. Letronne et al. / EBioMedicine 9 (2016) 278–292We suspect that further investigation of other potential ADAM30
substrates might provide a better understanding of the ADAM30-de-
pendent physiopathologic processes. Interestingly, all these targets
can be directly or indirectly linked to insulino-resistance and/or APP
metabolism. In one hand, GKAP1 was recently described to interact
with IRS1 and to participate in insulino-resistance in adypocites (Ando
et al., 2015) whereas the ADAM30 locus was reported as a genetic risk
factor for Type 2 diabetes (T2D) (Cerretti et al., 1999; Hu et al., 2009;
Ho et al., 2013; Almawi et al., 2013; Gupta et al., 2012; Ellis et al.,
2014). On the other hand, IRs, insulino-resistance and TD2 were de-
scribed as modulators of the Alzheimer's disease pathology though a
potential modulation of the APP metabolism whereas CTSD was previ-
ously involved in APP processing in vitro (Dreyer et al., 1994; Mackay
et al., 1997; Haque et al., 2008; Funk andKuret, 2012). It is also notewor-
thy that IRS4 (also identified in our COFRADIC study) is able to directly
interact with the Grb2 adaptor protein, a well-known actor of APP pro-
cessing/sorting (Hinsby et al., 2004). Of note, since lysosomal proteoly-
sis can represent a general mechanism for protein degradation/
processing, we measured secreted catabolites of Met, a protein
exhibiting a metabolism similar of APP (Lefebvre et al., 2012). We did
not observe any modifications of the secreted Met products following
co-transfection of Met and ADAM30 in HEK293 cells (Fig. S11). This ob-
servation suggests that the ADAM30-dependent CTSD-lysosome activa-
tion may be rather selective and that its metabolic consequences could
be limited to a restricted number of proteins.
When considering the APPmetabolism as a whole, our present find-
ings (including the ADAM30-linked decreased secretions of APPs-α and
-β and Aβ peptides) strongly suggest that either (i) ADAM30 is involved
in a process that modifies the equilibrium between APP recycling (from
early/late lysosomes to the membrane) and APP degradation in the ly-
sosome or (ii) ADAM30 affects the cellular events that drives the
dispatching of full-length membrane APP to either the endocytosis
pathway or the lysosomal compartment, as was previously suggested
(Lorenzen et al., 2010). However, it is noteworthy thatwe did not detect
any changes in the internalization or endocytosis of full-length mem-
brane APP in cells overexpressing ADAM30.
In conclusion, we hypothesize that ADAM30 is a key player in APP
metabolism; it appears to be involved in APP degradation via sorting
to lysosomes, targeted CTSD activation and then full-length APP
recycling. The mechanisms that involve ADAM30 may restrict full-
length APP recycling and therefore influence the pool of APP available
for α-, β- and γ-secretase processing.
In conclusion, we characterized a new facet of the APP physiology
which may provide new therapeutic targets to control amyloid peptide
production in the brain.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.06.002.
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